http://hl7.org/fhir/uv/ebm/PublicationRecord/179630
type: PublicationRecord
resource definition: 1.0
resource definition: .0
node role: treeRoot
id:
  v: 179630
meta:
  version id:
    v: 19
  last updated:
    v: 2025-10-13T12:34:35.118Z
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation
    l: journal-article-citation
language:
  v: en
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: PublicationRecord 179630 version: 19; Last updated: 2025-10-13 12:34:35+0000 Profile: JournalArticleCitation ArtifactPublicationStatus: Active url: https://fevir.net/resources/PublicationRecord/179630 identifier: FEvIR Object Identifier/179630, https://pubmed.ncbi.nlm.nih.gov/26092557 title: 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer. status: Active author: Computable Publishing®: MEDLINE-to-FEvIR Converter: publisher: Computable Publishing LLC contact: support@computablepublishing.com description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide. UseContexts - Code Value[x] * Citation Classification Type: fevir-platform-use (FEvIR Platform Use) Medline Base copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/ approvalDate: 2016-04-14 lastReviewDate: 2024-02-10 classification type: Citation Source classifier: MEDLINE classification type: MEDLINE Citation Owner classifier: National Library of Medicine, Index Section currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish statusDate activity: PubMed Pubstatus of Received period: ?? --> 2015-02-20 statusDate activity: PubMed Pubstatus of Revised period: ?? --> 2015-05-08 statusDate activity: PubMed Pubstatus of Accepted period: ?? --> 2015-05-11 statusDate activity: PubMed Pubstatus of Entrez period: ?? --> 2015-06-21 06:00:00+0000 statusDate activity: PubMed Pubstatus of Pubmed period: ?? --> 2015-06-21 06:00:00+0000 statusDate activity: PubMed Pubstatus of Medline period: ?? --> 2016-04-15 06:00:00+0000 citedArtifact identifier: https://pubmed.ncbi.nlm.nih.gov/26092557, https://doi.org/10.1016/j.urolonc.2015.05.012, pii/S1078-1439(15)00235-5 Titles - Type Language Text * Primary title English Feasibility study of a randomized control…
contained: ArtifactAssessment
  id:
    v: keywords0
  artifact: Reference
    l: #
    reference:
      v: #
    type:
      v: PublicationRecord
      l: PublicationRecord
  content:
    classifier:
      text:
        v: Androgen deprivation therapy
  content:
    classifier:
      text:
        v: Docetaxel
  content:
    classifier:
      text:
        v: Prostate cancer
  content:
    classifier:
      text:
        v: Prostatic biopsy
contained: Practitioner
  id:
    v: contributor0
  name:
    family:
      v: Rajan
    given:
      v: Prabhakar
contained: Practitioner
  id:
    v: contributor1
  name:
    family:
      v: Frew
    given:
      v: John A
contained: Practitioner
  id:
    v: contributor2
  name:
    family:
      v: Wilson
    given:
      v: James M
contained: Practitioner
  id:
    v: contributor3
  name:
    family:
      v: Azzabi
    given:
      v: Ashraf S T
contained: Practitioner
  id:
    v: contributor4
  name:
    family:
      v: McMenemin
    given:
      v: Rhona M
contained: Practitioner
  id:
    v: contributor5
  name:
    family:
      v: Stockley
    given:
      v: Jacqueline
contained: Practitioner
  id:
    v: contributor6
  name:
    family:
      v: Soomro
    given:
      v: Naeem A
contained: Practitioner
  id:
    v: contributor7
  name:
    family:
      v: Durkan
    given:
      v: Garrett
contained: Practitioner
  id:
    v: contributor8
  name:
    family:
      v: Pedley
    given:
      v: Ian D
contained: Practitioner
  id:
    v: contributor9
  name:
    family:
      v: Leung
    given:
      v: Hing Y
contained: ArtifactAssessment
  id:
    v: meshHeading0
  artifact: Reference
    l: #
    reference:
      v: #
    type:
      v: PublicationRecord
      l: PublicationRecord
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D000368
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D000726
    free to share:
      v: true
    component:
      classifier: Q000008
    component:
      classifier: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D001706
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: http://id.nlm.nih.gov/mesh/D000077143
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D005240
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D006801
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D008297
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D008875
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D011471

v: mesh-heading

v: MeSH heading

v: D000368

v: Aged

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D000726

v: Androgen Antagonists

v: false

v: qualifier

v: is not a major topic

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000008
display:
  v: administration & dosage

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: mesh-heading

v: MeSH heading

v: D001706

v: Biopsy

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D000077143

v: Docetaxel

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D005240

v: Feasibility Studies

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D006801

v: Humans

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D008297

v: Male

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D008875

v: Middle Aged

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D011471

v: Prostatic Neoplasms

v: false

v: true

type:
  text:
    v: qualifier
classifier:
  text:
    v: is not a major topic

type:
  text:
    v: qualifier
classifier: Q000188
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: Q000188
    display:
      v: drug therapy
component:
  type:
    text:
      v: is Major topic
  classifier:
    coding:
      system:
        v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
        l: Thesaurus.owl
      code:
        v: C49488
      display:
        v: Yes

type:
  text:
    v: qualifier
classifier: Q000601
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: Q000601
    display:
      v: surgery
component:
  type:
    text:
      v: is Major topic
  classifier:
    coding:
      system:
        v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
        l: Thesaurus.owl
      code:
        v: C49488
      display:
        v: Yes

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D043823
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D043823
    display:
      v: Taxoids
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic
component:
  type:
    text:
      v: qualifier
  classifier: Q000008
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000008
      display:
        v: administration & dosage
  component:
    type:
      text:
        v: is Major topic
component:
  type:
    text:
      v: qualifier
  classifier: Q000627
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000627
      display:
        v: therapeutic use
  component:
    type:
      text:
        v: is Major topic

v: C49487

v: No

v: C49488

v: Yes

url:
  v: http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status
  l: artifact-publication-status
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-status-type
      l: cited-artifact-status-type
    code:
      v: active
    display:
      v: Active

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v2-0203
      l: v2-0203
    code:
      v: ACSN
    display:
      v: Accession ID
  text:
    v: FEvIR Object Identifier
system:
  v: https://fevir.net/FOI
  l: FOI
value:
  v: 179630
assigner:
  display:
    v: Computable Publishing LLC

system:
  v: https://pubmed.ncbi.nlm.nih.gov
  l: pubmed.ncbi.nlm.nih.gov
value:
  v: 26092557

v: 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.

v: active

name:
  v: Computable Publishing®: MEDLINE-to-FEvIR Converter

v: Computable Publishing LLC

telecom:
  system:
    v: email

v: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

code:
  system:
    v: http://terminology.hl7.org/CodeSystem/citation-classification-type
    l: citation-classification-type
  code:
    v: fevir-platform-use
  display:
    v: FEvIR Platform Use
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: medline-base
    display:
      v: Medline Base
    user selected:
      v: false

v: 2016-04-14

v: 2024-02-10

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: citation-source
    display:
      v: Citation Source
classifier:
  text:
    v: MEDLINE

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: medline-owner
    display:
      v: MEDLINE Citation Owner
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value
      l: owner value
    code:
      v: NLM
    display:
      v: National Library of Medicine, Index Section
    user selected:
      v: false

coding:
  system:
    v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
    l: publicationrecord-status-type
  code:
    v: medline-medline
  display:
    v: Medline Citation Status of Medline

coding:
  system:
    v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
    l: publicationrecord-status-type
  code:
    v: pubmed-publication-status-ppublish
  display:
    v: PubMed PublicationStatus of ppublish

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-received
    display:
      v: PubMed Pubstatus of Received
period:
  end:
    v: 2015-02-20

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-revised
    display:
      v: PubMed Pubstatus of Revised
period:
  end:
    v: 2015-05-08

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-accepted
    display:
      v: PubMed Pubstatus of Accepted
period:
  end:
    v: 2015-05-11

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-entrez
    display:
      v: PubMed Pubstatus of Entrez
period:
  end:
    v: 2015-06-21T06:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-pubmed
    display:
      v: PubMed Pubstatus of Pubmed
period:
  end:
    v: 2015-06-21T06:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-medline
    display:
      v: PubMed Pubstatus of Medline
period:
  end:
    v: 2016-04-15T06:00:00.000Z

identifier:
  system:
    v: https://pubmed.ncbi.nlm.nih.gov
    l: pubmed.ncbi.nlm.nih.gov
  value:
    v: 26092557
identifier:
  system:
    v: https://doi.org
    l: doi.org
  value:
    v: 10.1016/j.urolonc.2015.05.012
identifier:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/v2-0203
        l: v2-0203
      code:
        v: ACSN
      display:
        v: Accession ID
    text:
      v: pii
  value:
    v: S1078-1439(15)00235-5
title:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/title-type
        l: title-type
      code:
        v: primary
      display:
        v: Primary title
  language:
    v: en
  text:
    v: Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
abstract:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type
        l: cited-artifact-abstract-type
      code:
        v: primary-human-use
      display:
        v: Primary human use
  text:
    v: **BACKGROUND AND OBJECTIVE:** Sequential tissue biopsies taken during clinical trials of novel systemic anticancer therapies for advanced prostate cancer (PCa) may aid pharmacodynamic evaluation and biomarker discovery. We conducted a single institution phase-II open-labeled randomized study to assess the safety, tolerability, and early efficacy of docetaxel chemotherapy plus androgen deprivation therapy (ADT) vs. ADT alone for patients with advanced non-castration-resistant PCa with sequential prostatic biopsies. **PATIENTS AND METHODS:** We randomized 30 patients with newly diagnosed high-grade locally advanced or metastatic (cT3-4/N0-1/M0-1) PCa to receive ADT with (n = 15) or without (n = 15) docetaxel. Transrectal ultrasound-guided prostatic biopsies were taken at randomization and ~22 weeks after treatment initiation. Primary end point: biochemical response rate. Secondary end points: time to progression and tumor profiling. **RESULTS:** Both treatments appear to be well tolerated, and there was no difference in mean nadir prostate-specific antigen and time to prostate-specific antigen relapse between treatment arms (P>0.05). No adverse effects of pre- and post-treatment prostatic biopsies were observed. The study was neither designed nor sufficiently powered to demonstrate statistically significant differences in oncological outcomes or safety profiles between the 2 treatment arms. **CONCLUSIONS:** Despite the lack of statistical power, our study suggests that docetaxel and ADT in combination may be well tolerated with apparently similar short-term efficacy compared with ADT alone for high-grade locally advanced or metastatic non-castration-resistant PCa, Sequential prostatic biopsies may provide tissue for tumor profiling to yield mechanistic or prognostic insights relating to novel systemic anticancer therapies.
  copyright:
    v: Copyright © 2015 Elsevier Inc. All rights reserved.
publication form:
  published in:
    identifier:
      system:
        v: https://portal.issn.org
        l: portal.issn.org
      value:
        v: 1873-2496
    identifier:
      system:
        v: https://www.issn.org/services/online-services/access-to-the-ltwa/
        l: access-to-the-ltwa
      value:
        v: Urol Oncol
    identifier:
      system:
        v: https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/
        l: the-issn-l-for-publications-on-multiple-media
      value:
        v: 1078-1439
    identifier:
      system:
        v: https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html
        l: contructitleabbre.html
      value:
        v: Urol Oncol
    identifier:
      system:
        v: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
        l: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
      value:
        v: 9805460
    title:
      v: Urologic oncology
    publisher location:
      v: United States
  cited medium:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-medium
        l: cited-medium
      code:
        v: internet
      display:
        v: Internet
  volume:
    v: 33
  issue:
    v: 8
  article date:
    v: 2015-08
  page string:
    v: 337.e1-6
publication form:
  cited medium:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-medium
        l: cited-medium
      code:
        v: internet-without-issue
      display:
        v: Internet without issue
  article date:
    v: 2015-06-16
web location:
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
        l: artifact-url-classifier
      code:
        v: abstract
      display:
        v: Abstract
  url:
    v: https://pubmed.ncbi.nlm.nih.gov/26092557/
    l: https://pubmed.ncbi.nlm.nih.gov/26092557/
web location:
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
        l: artifact-url-classifier
      code:
        v: doi-based
      display:
        v: DOI Based
  url:
    v: https://doi.org/10.1016/j.urolonc.2015.05.012
    l: j.urolonc.2015.05.012
classification:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: publishing-model
      display:
        v: Publishing Model
      user selected:
        v: false
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: Print-Electronic
      display:
        v: Print Electronic
      user selected:
        v: false
classification:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: keyword
      display:
        v: Keyword
      user selected:
        v: false
  artifact assessment:
    l: keywords0
    reference:
      v: #keywords0
    type:
      v: ArtifactAssessment
      l: ArtifactAssessment
    display:
      v: Keywords provided by NOTNLM
classification:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: chemical
      display:
        v: Chemical
      user selected:
        v: false
  classifier: D000726
  classifier: D043823
  classifier: http://id.nlm.nih.gov/mesh/D000077143

v: D020492

v: Periodical

system:
  v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn
  l: issn
code:
  v: Electronic
display:
  v: Electronic

v: Electronic ISSN Type

system:
  v: http://terminology.hl7.org/CodeSystem/v2-0203
  l: v2-0203
code:
  v: XX
display:
  v: Organization identifier

v: ISOAbbreviation

system:
  v: http://terminology.hl7.org/CodeSystem/v2-0203
  l: v2-0203
code:
  v: XX
display:
  v: Organization identifier

v: ISSN Linking

system:
  v: http://terminology.hl7.org/CodeSystem/v2-0203
  l: v2-0203
code:
  v: XX
display:
  v: Organization identifier

v: Medline Title Abbreviation

system:
  v: http://terminology.hl7.org/CodeSystem/v2-0203
  l: v2-0203
code:
  v: XX
display:
  v: Organization identifier

v: NLM Unique ID

D000726
coding:
  system:
    v: https://www.nlm.nih.gov/mesh
    l: mesh
  code:
    v: D000726
  display:
    v: Androgen Antagonists
  user selected:
    v: false

D043823
coding:
  system:
    v: https://www.nlm.nih.gov/mesh
    l: mesh
  code:
    v: D043823
  display:
    v: Taxoids
  user selected:
    v: false

http://id.nlm.nih.gov/mesh/D000077143
coding:
  system:
    v: https://www.cas.org/support/documentation/chemical-substances
    l: chemical-substances
  code:
    v: 15H5577CQD
  user selected:
    v: false
coding:
  system:
    v: https://www.nlm.nih.gov/mesh
    l: mesh
  code:
    v: D000077143
  display:
    v: Docetaxel
  user selected:
    v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
artifact assessment:
  l: meshHeading0
  reference:
    v: #meshHeading0
  type:
    v: ArtifactAssessment
    l: ArtifactAssessment

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publication-type
    display:
      v: Publication type
classifier: D017427
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D017427
    display:
      v: Clinical Trial, Phase II
    user selected:
      v: false
classifier: D016428
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false
classifier: D016449
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016449
    display:
      v: Randomized Controlled Trial
    user selected:
      v: false
classifier: D013485
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D013485
    display:
      v: Research Support, Non-U.S. Gov't
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: knowledge-artifact-type
    display:
      v: Knowledge Artifact Type
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false
artifact assessment:
  display:
    v: Classifier added by Computable Publishing LLC

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: citation-subset
    display:
      v: Citation subset
    user selected:
      v: false
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset
      l: citationsubset
    code:
      v: IM
    display:
      v: IM
    user selected:
      v: false

complete:
  v: true
entry:
  contributor:
    l: contributor0
    reference:
      v: #contributor0
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Rajan P
  forename initials:
    v: P
  affiliation:
    display:
      v: Institute of Cancer Sciences, University of Glasgow, UK. Electronic address: p.rajan@beatson.gla.ac.uk.
entry:
  contributor:
    l: contributor1
    reference:
      v: #contributor1
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Frew JA
  forename initials:
    v: JA
  affiliation:
    display:
      v: Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
entry:
  contributor:
    l: contributor2
    reference:
      v: #contributor2
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Wilson JM
  forename initials:
    v: JM
  affiliation:
    display:
      v: Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
entry:
  contributor:
    l: contributor3
    reference:
      v: #contributor3
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Azzabi AS
  forename initials:
    v: AS
  affiliation:
    display:
      v: Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
entry:
  contributor:
    l: contributor4
    reference:
      v: #contributor4
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: McMenemin RM
  forename initials:
    v: RM
  affiliation:
    display:
      v: Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
entry:
  contributor:
    l: contributor5
    reference:
      v: #contributor5
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Stockley J
  forename initials:
    v: J
  affiliation:
    display:
      v: Institute of Cancer Sciences, University of Glasgow, UK.
entry:
  contributor:
    l: contributor6
    reference:
      v: #contributor6
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Soomro NA
  forename initials:
    v: NA
  affiliation:
    display:
      v: Newcastle Urology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
entry:
  contributor:
    l: contributor7
    reference:
      v: #contributor7
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Durkan G
  forename initials:
    v: G
  affiliation:
    display:
      v: Newcastle Urology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
entry:
  contributor:
    l: contributor8
    reference:
      v: #contributor8
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Pedley ID
  forename initials:
    v: ID
  affiliation:
    display:
      v: Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
entry:
  contributor:
    l: contributor9
    reference:
      v: #contributor9
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Leung HY
  forename initials:
    v: HY
  affiliation:
    display:
      v: Institute of Cancer Sciences, University of Glasgow, UK; Cancer Research UK Beatson Institute, Bearsden, UK. Electronic address: h.leung@beatson.gla.ac.uk.